UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting strong growth in demand alongside its steady commercial expansion. Furthermore, preliminary October figures indicated that demand revenue more than doubled compared to the previous three months. This growth reflects the increasing adoption of physicians amid operational delays. The company closed the quarter with $127.4 million in cash and marketable securities. As the permanent billing code takes effect in early 2026, UroGen Pharma Ltd. (NASDAQ:URGN) anticipates a smoother process, despite product uptake potentially facing administrative lags of up to 60 days due to reimbursement and coding complexities. Furthermore, the company noted an expansion of its sales force to 82 representatives. With this expansion, the company strengthened physician outreach and patient access across major payers, with co
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech SummitGlobeNewswire
- Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyGlobeNewswire
URGN
Earnings
- 11/6/25 - Beat
URGN
Sec Filings
- 2/4/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- URGN's page on the SEC website